People · Operator
Named in public records as an officer, director or promoter · active 2017–2020 · Other Technology, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| SkySpecs, Inc. | — | Other Technology | Series C | $127.3M | $78.7M | 2017 |
| Genomenon, Inc. | — | Biotechnology | Series B | $28.8M | $41.8M | 2020 |
| Fifth Eye Inc. | — | Other Technology | Series A | $14.7M | $81.6M | 2018 |
| Change Dynamix, Inc. | — | Other Technology | Pre-Seed | $1.2M | $33.7M | 2018 |
Charles Moret at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Charles Moret on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Roberts | 1 | 13 |
| Michael Klein | 1 | 9 |
| Michael Gross | 1 | 9 |
| WILLIAM SCHMIDT | 1 | 7 |
| JAMES ADOX | 1 | 5 |
| Thomas Shehab | 1 | 4 |
| Paul D'Amato | 1 | 4 |
| Tim Streit | 1 | 4 |
| Patricia Glaza | 1 | 3 |
| Peter Wells | 1 | 3 |
| Thomas Brady | 1 | 3 |
| Jennifer Baird | 1 | 3 |
| Daniel Ellis | 1 | 2 |
| Steve Schwartz | 1 | 2 |
| Sean Kearney | 1 | 2 |
| David Gregorka | 1 | 2 |
| Bill Leland Johnson | 1 | 1 |
| Sam Globus | 1 | 1 |
| Ashwin Belle | 1 | 1 |
| Mark Salamango | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.